drugset
drugset / Trial / NCT01415791

Oral Mucosal Absorption of ICI176,334-1

NCT01415791 ↗

Phase 1 Completed 8 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the presence or absence of oral mucosal absorption of ICI176,334-1

Timeline

Start
2011-08
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Bicalutamide Other / unclassified — —

Indications

No indication recorded.